Key HighlightsShares of TNGX climbed 45% following announcement of a 92% objective response rate in pancreatic cancer patients treated with vopimetostat combined with daraxonrasibAll 12 evaluable patients achieved disease control, with 90% remaining progression-free at the 6-month evaluation pointAn alternative combination—vopimetostat paired with zoldonrasib—demonstrated a 52% objective response rate among 27 enrolled patientsSafety profile remained favorable across both combinations; no Grade 4 or 5 serious events recorded, zero treatment withdrawalsThe company intends to initiate Phase 3 clinical trials for the vopimetostat/daraxonrasib combination targeting first-line MTAP-deleted pancreatic cancer during the second half of 2026Shares of Tango Therapeutics (TNGX) surged 45% during Monday’s premarket session following the biotechnology company’s announcement of promising early-phase clinical trial results demonstrating significant tumor reduction in patients battling advanced pancreatic cancer.Tango Therapeutics, Inc., TNGXThe standout figure: an impressive 92% objective response rate observed among participants receiving the combination therapy of vopimetostat alongside Revolution Medicines’ daraxonrasib. This translates to 11 out of 12 evaluable patients with metastatic pancreatic ductal adenocarcinoma experiencing positive treatment responses.The therapeutic combination also delivered a perfect 100% disease control rate. Among the responses recorded, nine of 11 received confirmation, while 90% of trial participants showed no disease progression at the critical 6-month evaluation point.The patient population consisted of individuals with second and third-line metastatic disease—meaning they had undergone previous unsuccessful treatments. More than 70% presented with liver metastases.As of the May 28 data cutoff, median progression-free survival remained unreached, typically considered an encouraging indicator during this trial phase.Trial participants received daily oral doses of either 200mg or 250mg vopimetostat, administered in combination with 100mg daraxonrasib once daily. The dataset encompassed 59 total patients enrolled across both pancreatic cancer and non-small cell lung cancer study arms.Secondary Combination Demonstrates Encouraging OutcomesTango simultaneously disclosed findings from an alternative drug pairing—vopimetostat combined with Revolution’s zoldonrasib—evaluated in 27 assessable pancreatic cancer patients.This treatment arm yielded a 52% objective response rate alongside a 74% progression-free survival rate at the 6-month milestone. Tumor shrinkage occurred in 14 of the 27 enrolled patients.While these results appear less dramatic compared to the daraxonrasib combination, the findings strengthen the evidence supporting vopimetostat’s therapeutic potential when paired with various combination partners.Both treatment combinations demonstrated favorable safety profiles. The majority of adverse events registered as Grade 1 or 2 in severity. Common side effects associated with the daraxonrasib combination included rash, stomatitis/mucositis, and diarrhea. Neither Grade 4 nor Grade 5 adverse events occurred, and patient retention remained at 100% with no discontinuations attributed to treatment-related side effects.Pipeline Advancement StrategyTango has announced plans to progress the vopimetostat plus daraxonrasib combination into Phase 3 clinical development. The primary target population: treatment-naive patients with first-line MTAP-deleted pancreatic cancer.The biotechnology firm anticipates completing Phase 3 trial design finalization during the latter half of 2026, contingent upon regulatory agency consultations.MTAP deletions are present in approximately 40% of pancreatic cancer cases and roughly 15% of lung cancer diagnoses—establishing a well-defined patient subset that provides clear genetic selection parameters for clinical trials.These results emerged just one week following Revolution Medicines’ presentation of daraxonrasib data at the ASCO conference, where the therapeutic agent demonstrated doubled survival outcomes in pancreatic cancer patients.Vopimetostat represents an oral therapeutic agent specifically engineered to selectively target malignant cells harboring MTAP deletions.Revolution Medicines (RVMD) stock declined 4.15% during the trading session.The post Tango Therapeutics (TNGX) Stock Soars 45% Following Breakthrough Pancreatic Cancer Data appeared first on Blockonomi.